Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01732718
Other study ID # 11-1354
Secondary ID R01HL111659
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2013
Est. completion date January 9, 2018

Study information

Verified date November 2018
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to learn about the effect of the drug, atorvastatin, on blood vessels in patients with sickle cell disease.

The primary hypothesis is that endothelial dysfunction is an important contributor to the pathophysiology of albuminuria in SCD. The investigators propose that atorvastatin will improve endothelial dysfunction, decrease levels of soluble fms-like tyrosine kinase-1 (sFLT-1), and decrease albuminuria in SCD patients.

Participants will be individuals with sickle cell disease, age 18 to 60, who have some degree of albuminuria. A total of 19 subjects, males and females, will be enrolled. The study is made up of Screening, Treatment, and Follow Up phases and has a cross-over design. After patients are screened for eligibility, they will be randomized to receive atorvastatin or placebo in the initial six-week treatment period. When that is complete, there will be a four-week washout period before they begin another six-week treatment period. In the second treatment period, they "cross-over" to the other treatment arm. Four weeks after the end of the second treatment period, follow-up safety assessments will be done.


Description:

It is well recognized that sickle cell disease (SCD) is characterized by a vasculopathy, with involvement of multiple organs including the brain, lung, spleen, and kidney. This results in multiple clinical complications, including ischemic stroke, pulmonary hypertension, autosplenectomy, as well as albuminuria and chronic renal disease. Several recent studies have confirmed the association of both albuminuria and renal dysfunction with echocardiographically-defined pulmonary hypertension and other vasculopathic complications in SCD, suggesting that they may share a similar pathophysiology. Despite the high prevalence of albuminuria in patients with SCD and the known association of renal failure with increased mortality, the pathophysiology and treatment of albuminuria in this setting remain poorly defined.

The treatment options for nephropathy in SCD are limited. Although Angiotensin converting enzyme (ACE) inhibitors are the "standard of care" in the treatment of patients with proteinuria, there are to date no controlled, long-term studies confirming their efficacy and safety in this setting.

In this study, the investigators will evaluate the efficacy and safety of atorvastatin in SCD patients. At the completion of this trial, the investigators will have an improved understanding of the contribution of endothelial dysfunction to the pathophysiology of albuminuria in SCD. If the data support the hypothesis that atorvastatin is safe and effective in this population, the investigators plan on carrying out adequately powered studies to more definitively evaluate its safety and efficacy in the treatment and/or prevention of albuminuria in SCD.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date January 9, 2018
Est. primary completion date January 9, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Sickle cell anemia (HbSS) or Sickle-beta0 thalassemia (HbS-beta0thal) between ages of 18 and 60;

2. albuminuria (micro- or macroalbuminuria, defined as =/> 30mg/g creatinine);

3. serum alanine aminotransferase (ALT) </= 2 times upper limits of normal and/or gamma-glutamyl transferase (GGT) </= 3 times upper limits of normal;

4. platelet count > 150,000 cu/mm;

5. normal baseline coagulation profile (PT, International Normalized Ratio (INR), and PTT);

6. non-crisis, steady state with no severe pain episodes during the preceding 4 weeks, and no documented infection in the 2 weeks prior to enrollment;

7. ability to understand the requirements of the study;

8. if a woman of childbearing potential, must use an adequate method of contraception; and

9. if receiving hydroxyurea, ACE inhibitors or angiotensin blockers (ARB), should be on a stable dose for at least 3 months.

Exclusion Criteria:

1. hypersensitivity to any component of atorvastatin, or history of adverse reaction to statins;

2. pregnant or breastfeeding;

3. on statin therapy;

4. history of metastatic cancer;

5. current history of alcohol abuse;

6. history of diabetes mellitus or poorly controlled systemic hypertension;

7. end-stage renal disease;

8. total cholesterol level < 80 mg/dL and LDL cholesterol > 130 mg/dL;

9. on a chronic transfusion program;

10. ingested any investigational drugs within the past 4 weeks;

11. prior history of any myopathy;

12. allergy to nitroglycerin;

13. taking any of the following drugs: phosphodiesterase-5 inhibitors (e.g., sildenafil), cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g., cyclosporine, protease inhibitors), macrolide antibiotics (e.g., clarithromycin, erythromycin), fibric acid derivatives (e.g. gemfibrozil), niacin, colchicines, antifungal agents (azole derivatives), amiodarone, danazol, daptomycin, diltiazem, verapamil, eltrombopag, everolimus, fosphenytoin, or lanthanum.

Patients will also be encouraged to avoid grape fruit juice and red yeast rice for the duration of the study.

Atorvastatin is contraindicated during pregnancy and breast-feeding.

Study Design


Intervention

Drug:
Atorvastatin
40 mg tablet by mouth daily for 6 weeks
Placebo
Matching placebo tablet by mouth daily for 6 weeks

Locations

Country Name City State
United States UNC School of Medicine Clinical&Translational Research Ctr Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Week 6 in Endothelial Function Endothelial function will be assessed using ultrasound imaging of the brachial artery, with measurement of endothelium-dependent (flow-mediated) and endothelium-independent (nitroglycerin-mediated) dilation of the artery measured in millimeters (mm). Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Plasma Markers of Endothelial Activation Investigators will measure plasma levels of soluble vascular cell adhesion molecules (sVCAM) and soluble intracellular adhesion molecule (sICAM) at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Heme Oxygenase Activity The expression and activity of heme oxygenase-1(HO-1)will be determined at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Plasma Levels of Soluble Fms-like Tyrosine Kinase-1 (sFLT-1) Investigators will measure plasma levels of soluble fms-like tyrosine kinase-1 (sFLT-1) at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Monocyte Activation Flow cytometry performed to assess monocyte activation at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Renal Function Investigators will assess the effect of atorvastatin on albuminuria by spot urine microalbuminuria/creatinine ratio measured at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Occurrence of Adverse Events. Subjects will be evaluated for safety by patient self-report of adverse events and results of laboratory tests. Continuously from randomization through end of study
Secondary Abnormal Physical Findings. Subjects will be evaluated by physical examination and/or measurement of vital signs at each study visit. Baseline, 2, 4, and 6 weeks during treatment, and at follow-up.
Secondary Change From Baseline to Week 6 in Rho/Rho Kinase Activity The expression and activity of rho/rho kinase will be determined at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Plasma Levels of Vascular Endothelial Growth Factor (VEGF) Investigators will measure plasma levels of vascular endothelial growth factor (VEGF) at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Mean Change From Baseline to Week 6 in Absolute Cell Counts Flow cytometry will be performed to assess absolute cell counts at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Tissue Factor (TF) Expression Flow cytometry will be performed to assess TF expression at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in TF-mediated sFLT Release From Monocytes Flow cytometry will be performed to assess TF-mediated sFLT release from monocytes at baseline and at 6 weeks of treatment. Baseline, 6 weeks
Secondary Change From Baseline to Week 6 in Tricuspid Regurgitant (TR) Jet. Echocardiogram will be used to assess TR jet before and after treatment. Baseline, Week 6
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1